Concord Biotech - Public Comps and Valuation Multiples

Concord Biotech Overview

About Concord Biotech

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.

Founded

1984

HQ

Employees

1.6K+

Website

concordbiotech.com

Sectors

Biopharmaceuticals
Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $148M

LTM EBITDA $60.5M

EV

$1.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Concord Biotech Financials

As of September 2025, Concord Biotech reported last 12-month revenue of $148M and EBITDA of $60.5M.

In the same period, Concord Biotech generated $111M in LTM gross profit and $43.5M in net income.

See Concord Biotech valuation multiples based on analyst estimates

Concord Biotech P&L

In the most recent fiscal year, Concord Biotech reported revenue of $133M and EBITDA of $62.0M.

Concord Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Concord Biotech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$148M	XXX	$133M	XXX	XXX	XXX
Gross Profit	$111M	XXX	$97.2M	XXX	XXX	XXX
Gross Margin	75%	XXX	73%	XXX	XXX	XXX
EBITDA	$60.5M	XXX	$62.0M	XXX	XXX	XXX
EBITDA Margin	41%	XXX	47%	XXX	XXX	XXX
EBIT	$53.9M	XXX	$52.3M	XXX	XXX	XXX
EBIT Margin	37%	XXX	39%	XXX	XXX	XXX
Net Profit	$43.5M	XXX	$41.9M	XXX	XXX	XXX
Net Margin	29%	XXX	31%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Concord Biotech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $148M. EBITDA for the last twelve months was $60.5M. In the most recent fiscal year, Concord Biotech achieved $133M in revenue and $62.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$148M	Analyst estimates available to subscribers	$133M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$111M	Analyst estimates available to subscribers	$97.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	75.3% gross margin	Analyst estimates available to subscribers	73.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$60.5M	Analyst estimates available to subscribers	$62.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	40.9% EBITDA margin	Analyst estimates available to subscribers	46.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$53.9M	Analyst estimates available to subscribers	$52.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	36.5% EBIT margin	Analyst estimates available to subscribers	39.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$43.5M	Analyst estimates available to subscribers	$41.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	29.5% net profit margin	Analyst estimates available to subscribers	31.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Concord Biotech

This financial data table provides comprehensive performance metrics for Concord Biotech, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Concord Biotech generated $148M in revenue over the last twelve months.
The company achieved $60.5M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $111M.
Net income over the last twelve months reached $43.5M.

Fiscal Year Performance

In the most recent fiscal year, Concord Biotech reported $133M in total revenue.
Fiscal year EBITDA was $62.0M.
The company maintained a gross profit margin of 73.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 46.6%.
Net profit margin reached 31.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Concord Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Concord Biotech Stock Performance

Concord Biotech has current market cap of INR 160B (or $1.8B), and EV of INR 157B (or $1.8B).

Market Cap Evolution

Concord Biotech Stock Data

As of October 17, 2025, Concord Biotech's stock price is INR 1533 (or $17).

See Concord Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.8B	$1.8B	XXX	XXX	XXX	XXX	$0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Concord Biotech Valuation Multiples

Concord Biotech's trades at 13.9x EV/Revenue multiple, and 29.7x EV/EBITDA.

See valuation multiples for Concord Biotech and 15K+ public comps

Concord Biotech Financial Valuation Multiples

As of October 17, 2025, Concord Biotech has market cap of $1.8B and EV of $1.8B.

Equity research analysts estimate Concord Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Concord Biotech has a P/E ratio of 41.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.8B	XXX	$1.8B	XXX	XXX	XXX
EV (current)	$1.8B	XXX	$1.8B	XXX	XXX	XXX
EV/Revenue	12.0x	XXX	13.9x	XXX	XXX	XXX
EV/EBITDA	29.3x	XXX	29.7x	XXX	XXX	XXX
EV/EBIT	32.9x	XXX	35.4x	XXX	XXX	XXX
EV/Gross Profit	16.0x	XXX	n/a	XXX	XXX	XXX
P/E	41.6x	XXX	45.1x	XXX	XXX	XXX
EV/FCF	78.7x	XXX	108.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Concord Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Concord Biotech Margins & Growth Rates

Concord Biotech's last 12 month revenue growth is 19%

Concord Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $29K for the same period.

Concord Biotech's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Concord Biotech's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Concord Biotech and other 15K+ public comps

Concord Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	19%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	41%	XXX	47%	XXX	XXX	XXX
EBITDA Growth	20%	XXX	13%	XXX	XXX	XXX
Rule of 40	66%	XXX	66%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	90%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$29K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	34%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial